Intermittent preventive treatment of malaria in pregnant women and infants: Making best use of the available evidence

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 12, 2012, Pages 1719-1736

  Bardají, Azucena ^a   Bassat, Quique ^a   Alonso, Pedro L ^a   Menéndez, Clara ^a  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

Control; Infancy; Intermittent preventive treatment; Malaria; Pregnancy

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; MEFLOQUINE; PYRIMETHAMINE PLUS SULFADOXINE;

ADAPTIVE IMMUNITY; BED NET; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; INFANT; INFECTION PREVENTION; INTERMITTENT PREVENTIVE TREATMENT; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MORTALITY; PATIENT COMPLIANCE; PLACENTA MALARIA; PREGNANCY; PREVENTIVE MEDICINE; REVIEW; RISK REDUCTION; SECOND TRIMESTER PREGNANCY; SINGLE DRUG DOSE; SKIN DISEASE; THIRD TRIMESTER PREGNANCY; VACCINATION;

ANTIMALARIALS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNITY, INNATE; INFANT; INFANT, NEWBORN; MALARIA; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC;

EID: 84864066704     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.703651     Document Type: Review

References (143)

1. Greenwood B. The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. Am J Trop Med Hyg 2004;70(1):1-7
2. Geerligs PD, Brabin BJ, Eggelte TA. Analysis of the effects of malaria chemoprophylaxis in children on haematological responses, morbidity and mortality. Bull World Health Organ 2003;81(3):205-216
3. UNICEF. The state of the world's children 2008. UNICEF; New York: 2007
4. WHO. World Health Organization. The World malaria Report 2009. Available from: Http://wwwwhoint/malaria/world-malaria-report-2009/en/indexhtml
5. van Eijk AM, Hill J, Alegana VA, et al. Coverage of malaria protection in pregnant women in sub-Saharan Africa: A synthesis and analysis of national survey data. Lancet Infect Dis 2011;11(3):190-207
6. WHO. WHO Policy recommendation on Intermittent Preventive Treatment during infancy with sulphadoxinepyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa,March 2010. Available from: Http://www.who.int/malaria/news/WHO-policy-recommendation-IPTi-032010.pdf 2010
7. WHO. Policy Recommendation: SEASONAL Malaria Chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel subregion in Africa, March 2012. Available from: Http://www.who.int/ malaria/publications/atoz/who-smc-policy-recommendation/en/index.html
8. White NJ. Intermittent presumptive treatment for malaria. PLoS Med 2005;2(1):e3
9. Greenwood B. Intermittent preventive antimalarial treatment in infants. Clin Infect Dis 2007;45(1):26-28
10. Cairns M, Carneiro I, Milligan P, et al. Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PLoS ONE 2008;3(5):e2227
11. May J, Adjei S, Busch W, et al. Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon. Malar J 2008;7:198
12. WHO. Policy recommendation on Intermittent Preventive Treatment during infancy with sulphadoxinepyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa, March 2010. Available from: Http://www.who.int/ malaria/news/WHO-policy-recommendation-IPTi-032010.pdf.2010
13. Chandramohan D, Owusu-Agyei S, Carneiro I, et al. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 2005;331(7519):727-733
14. Macete E, Aide P, Aponte JJ, et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: A randomized, placebo-controlled trial. J Infect Dis 2006;194(3):276-285
15. Kobbe R, Kreuzberg C, Adjei S, et al. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin Infect Dis 2007;45(1):16-25
16. Grobusch MP, Lell B, Schwarz NG, et al. Intermittent preventive treatment against malaria in infants in Gabon-a randomized, double-blind, placebo-controlled trial. J Infect Dis 2007;196(11):1595-1602
17. Mockenhaupt FP, Reither K, Zanger P, et al. Intermittent preventive treatment in infants as a means of malaria control: A randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrob Agents Chemother 2007;51(9):3273-3281
18. Aponte JJ, Schellenberg D, Egan A, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: A pooled analysis of six randomised, placebo-controlled trials. Lancet 2009;374(9700):1533-1542
19. Schellenberg D, Menendez C, Aponte JJ, et al. Intermittent preventive antimalarial treatment for Tanzanian infants: Follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 2005;365(9469):1481-1483
20. Sutherland CJ, Drakeley CJ, Schellenberg D. How is childhood development of immunity to plasmodium falciparum enhanced by certain antimalarial interventions? Malar J 2007;6:161
21. Schellenberg D, Menendez C, Kahigwa E, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: A randomised, placebo-controlled trial. Lancet 2001;357(9267):1471-1477
22. Menendez C, Schellenberg D, Macete E, et al. Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: Public health implications. Malar J 2007;6:132
23. Odhiambo FO, Hamel MJ, Williamson J, et al. Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: A randomized, double-blind placebo-controlled trial. PLoS One 2010;5(4):e10016
24. Menendez C, D'Alessandro U, ter Kuile FO. Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis 2007;7(2):126-135
25. Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007;7(2):93-104
26. Menendez C, Bardaji A, Sigauque B, et al. A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS One 2008;3(4):e1934
27. Mbaye A, Richardson K, Balajo B, et al. A randomized, placebo-controlled trial of intermittent preventive treatment with sulphadoxine-pyrimethamine in Gambian multigravidae. Trop Med Int Health 2006;11(7):992-1002
28. Njagi JK, Magnussen P, Estambale B, et al. Prevention of anaemia in pregnancy using insecticide-treated bednets and sulfadoxine-pyrimethamine in a highly malarious area of Kenya: A randomized controlled trial. Trans R Soc Trop Med Hyg 2003;97(3):277-282
29. Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine- pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 1998;59(5):813-822
30. Schultz LJ, Steketee RW, Macheso A, et al. The efficacy of antimalarial regimens containing sulfadoxinepyrimethamine and/or chloroquine in preventing peripheral and placental plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 1994;51(5):515-522
31. Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxinepyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: A randomised placebo-controlled trial. Lancet 1999;353(9153):632-636
32. WHO. WHO expert committee on malaria. World Health Organization; Geneva: 2000
33. WHO. A strategic framework for malaria prevention and control during pregnancy in the African region. World Health Organization; Geneva: 2004; AFR/MAL
34. Hamer DH, Mwanakasale V, Macleod WB, et al. Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women. J Infect Dis 2007;196(11):1585-1594
35. Menendez C, Bardaji A, Sigauque B, et al. Malaria prevention with IPTp during pregnancy reduces neonatal mortality. PLoS One 2010;5(2):e9438
36. Maiga OM, Kayentao K, Traore BT, et al. Superiority of 3 over 2 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria during pregnancy in mali: A randomized controlled trial. Clin Infect Dis 53(3):215-223
37. Greenwood BM, Greenwood AM, Snow RW, et al. The effects of malaria chemoprophylaxis given by traditional birth attendants on the course and outcome of pregnancy. Trans R Soc Trop Med Hyg 1989;83(5):589-594
38. Bardaji A, Sigauque B, Sanz S, et al. Impact of malaria at the end of pregnancy on infant mortality and morbidity. J Infect Dis 2011;691-699
39. Armstrong Schellenberg JR, Shirima K, Maokola W, et al. Community effectiveness of intermittent preventive treatment for infants (IPTi) in rural southern Tanzania. Am J Trop Med Hyg 2010;82(5):772-781
40. Gosling RD, Gesase S, Mosha JF, et al. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: A randomised, double-blind, placebo-controlled trial. Lancet 2009;374(9700):1521-1532
41. Schellenberg D, Cisse B, Menendez C. The IPTi consortium: Research for policy and action. Trends Parasitol 2006;22(7):296-300
42. Gosling RD, Carneiro I, Chandramohan D. Intermittent preventive treatment of malaria in infants: How does it work and where will it work? Trop Med Int Health 2009;14(9):1003-1010
43. Institute of Medicine: COMMITTEE on the perspectives of the role of intermittent preventive treatment for malaria in infants. Assessment of the role of intermittent preventive treatment for malaria in infants: LETTER report. Available from: Http://www.nap.edu/catalog/12180.htlm 2008
44. Senn N, Rarau P, Stanisic DI, et al. Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to plasmodium falciparum and P. vivax: A randomized controlled trial. PLoS Med 2012;9(3):e1001195
45. Massaga JJ, Kitua AY, Lemnge MM, et al. Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: A randomised placebo-controlled trial. Lancet 2003;361(9372):1853-1860
46. Willey BA, Armstrong Schellenberg JR, Maokola W, et al. Evaluating the effectiveness of IPTi on malaria using routine health information from sentinel health centres in southern Tanzania. Malar J 2011;10(1):41
47. De Sousa A, Salama P, Chopra M. Implementing intermittent preventive treatment in infants. Lancet 2010; 375 (9709):121
48. Mayor A, Serra-Casas E, Sanz S, et al. Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants. J Infect Dis 2008;197(12): 1737-42
49. Bjorkman A, Phillips-Howard PA. Adverse reactions to sulfa drugs: Implications for malaria chemotherapy. Bull World Health Organ 1991;69(3):297-304
50. Briand V, Bottero J, Noel H, et al. Intermittent treatment for the prevention of malaria during pregnancy in Benin: A randomized, open-label equivalence trial comparing sulfadoxinepyrimethamine with mefloquine. J Infect Dis 2009;200(6): 991-1001
51. Sevene E, Gonzalez R, Menendez C. Current knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy. Expert Opin Pharmacother 2010;11(8): 1277-93
52. World Health Organization (WHO). A strategic framework for malaria prevention and control during pregnancy in the African region: Report AFR/MAL/04/01. WHO Regional Office for Africa; Brazzaville, Democratic Republic of Congo: 2006
53. Taylor WR, White NJ. Antimalarial drug toxicity: A review. Drug Saf 2004;27(1):25-61
54. Steffen R, Somaini B. Severe cutaneous adverse reactions to sulfadoxinepyrimethamine in Switzerland. Lancet 1986;1(8481):610
55. Nyunt MM, Adam I, Kayentao K, et al. Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Clin Pharmacol Ther 2009;87(2):226-234
56. Luzzatto L. The rise and fall of the antimalarial Lapdap: A lesson in pharmacogenetics. Lancet 2010;376(9742):739-741
57. Menendez C, Kahigwa E, Hirt R, et al. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 1997;350(9081):844-850
58. Pringle G, Avery-Jones S. Observations on the early course of untreated falciparum malaria in semi-immune African children following a short period of protection. Bull World Health Organ 1966;34(2):269-272
59. Hogh B, Thompson R, Lobo V, et al. The influence of maloprim chemoprophylaxis on cellular and humoral immune responses to plasmodium falciparum asexual blood stage antigens in schoolchildren living in a malaria endemic area of Mozambique. Acta Trop 1994;57(4):265-277
60. Greenwood BM, Greenwood AM, Smith AW, et al. A comparative study of lapudrine (chlorproguanil) and maloprim (pyrimethamine and dapsone) as chemoprophylactics against malaria in Gambian children. Trans R Soc Trop Med Hyg 1989;83(2):182-188
61. Greenwood BM, David PH, Otoo-Forbes LN, et al. Mortality and morbidity from malaria after stopping malaria chemoprophylaxis. Trans R Soc Trop Med Hyg 1995;89(6):629-633
62. Laing AB. The impact of malaria chemoprophylaxis in Africa with special reference to Madagascar, Cameroon, and Senegal. Bull World Health Organ 1984;62(Suppl):41-48
63. Grobusch MP, Gabor JJ, Aponte JJ, et al. No rebound of morbidity following intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Gabon. J Infect Dis 2009;200(11):1658-1661
64. Quelhas D, Puyol L, Quinto L, et al. Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage plasmodium falciparum antigens in infants in Mozambique. Clin Vaccine Immunol 2008;15(8):1282-1291
65. Rosen JB, Breman JG. Malaria intermittent preventive treatment in infants, chemoprophylaxis, and childhood vaccinations. Lancet 2004;363(9418):1386-1388
66. Rosen JB, Breman JG, Manclark CR, et al. Malaria chemoprophylaxis and the serologic response to measles and diphtheria-tetanus-whole-cell pertussis vaccines. Malar J 2005;4:53
67. World Health Organization. Report of the Technical Consultation on Intermittent Preventive Treatment in Infants (IPTi), Technical Expert Group on Preventive Chemotherapy. WHO/HQ; Geneva, Switzerland: 2009
68. Rasheed FN, Bulmer JN, De Francisco A, et al. Relationships between maternal malaria and malarial immune responses in mothers and neonates. Parasite Immunol 1995;17(1):1-10
69. Serra-Casas E, Menendez C, Bardaji A, et al. The effect of intermittent preventive treatment during pregnancy on malarial antibodies depends on HIV status and is not associated with poor delivery outcomes. J Infect Dis 2009;201(1):123-131
70. Xi G, Leke RG, Thuita LW, et al. Congenital exposure to plasmodium falciparum antigens: Prevalence and antigenic specificity of in utero-produced antimalarial immunoglobulin M antibodies. Infect Immun 2003;71(3):1242-1246
71. Broen K, Brustoski K, Engelmann I, Luty AJ. Placental plasmodium falciparum infection: Causes and consequences of in utero sensitization to parasite antigens. Mol Biochem Parasitol 2007;151(1):1-8
72. Dembo EG, Mwapasa V, Montgomery J, et al. Impact of human immunodeficiency virus infection in pregnant women on variant-specific immunity to malaria. Clin Vaccine Immunol 2008;15(4):617-621
73. Serra-Casas E, Menendez C, Bardaji A, et al. The effect of intermittent preventive treatment during pregnancy on malarial antibodies depends on HIV status and is not associated with poor delivery outcomes. J Infect Dis 2010;201(1):123-131
74. Egan A, Crawley J, Schellenberg D. Intermittent preventive treatment for malaria control in infants: Moving towards evidence-based policy and public health action. Trop Med Int Health 2005;10(9):815-817
75. Mockenhaupt FP, Bedu-Addo G, Eggelte TA, et al. Rapid increase in the prevalence of sulfadoxine-pyrimethamine resistance among plasmodium falciparum isolated from pregnant women in Ghana. J Infect Dis 2008;198(10):1545-1549
76. Roper C, Pearce R, Bredenkamp B, et al. Antifolate antimalarial resistance in southeast Africa: A population-based analysis. Lancet 2003;361(9364): 1174-81
77. Kublin JG, Dzinjalamala FK, Kamwendo DD, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of plasmodium falciparum malaria. J Infect Dis 2002;185(3):380-388
78. Schellenberg D, Kahigwa E, Drakeley C, et al. The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 2002;67(1):17-23
79. Mockenhaupt FP, Ehrhardt S, Dzisi SY, et al. A randomized, placebo-controlled, double-blind trial on sulfadoxinepyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Trop Med Int Health 2005;10(6):512-520
80. Abacassamo F, Enosse S, Aponte JJ, et al. Efficacy of chloroquine, amodiaquine, sulphadoxinepyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop Med Int Health 2004;9(2):200-208
81. Alloueche A, Bailey W, Barton S, et al. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: Double-blind randomised controlled trial. Lancet 2004;363(9424):1843-1848
82. Oduro AR, Anyorigiya T, Hodgson A, et al. A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana. Trop Med Int Health 2005;10(3):279-284
83. Grobusch MP, Egan A, Gosling RD, Newman RD. Intermittent preventive therapy for malaria: Progress and future directions. Curr Opin Infect Dis 2007;20(6):613-620
84. Menendez C, Serra-Casas E, Scahill MD, et al. HIV and placental infection modulate the appearance of drug-resistant plasmodium falciparum in pregnant women who receive intermittent preventive treatment. Clin Infect Dis 2011;52(1):41-48
85. Faye B, Ndiaye M, Ndiaye JL, et al. Prevalence of molecular markers of plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal. Parasitol Res 2011;109(1):133-138
86. Dicko A, Sagara I, Djimde AA, et al. Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali. Malar J 2010;9:9
87. Harrington WE, Mutabingwa TK, Kabyemela E, et al. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis 2011;53(3):224-230
88. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: A systematic review. JAMA 2007;297(23):2603-2616
89. Kalanda GC, Hill J, Verhoeff FH, Brabin BJ. Comparative efficacy of chloroquine and sulphadoxine-pyrimethamine in pregnant women and children: A meta-analysis. Trop Med Int Health 2006;11(5):569-577
90. Tagbor H, Bruce J, Browne E, et al. Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: A randomised trial. Lancet 2006;368(9544):1349- 1356
91. O'Meara WP, Smith DL, McKenzie FE. Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria. PLoS Med 2006;3(5):e141
92. Report of the Technical Expert Group (TEG). Meeting on Intermittent Preventive Therapy in Infancy (IPTi), Geneva, 8-10 October 2007. Available from: Http://malaria.who.int/docs/IPTi/TEGConsultIPTiOct2007Report.pdf
93. MacArthur J, Stennies GM, Macheso A, et al. Efficacy of mefloquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated plasmodium falciparum infection in Machinga District, Malawi, 1998. Am J Trop Med Hyg 2001;65(6):679-684
94. Matteelli A, Saleri N, Bisoffi Z, et al. Mefloquine versus quinine plus sulphalene-pyrimethamine (metakelfin) for treatment of uncomplicated imported falciparum malaria acquired in Africa. Antimicrob Agents Chemother 2005;49(2):663-667
95. Adam I, Ali DA, Alwaseila A, et al. Mefloquine in the treatment of falciparum malaria during pregnancy in Eastern Sudan. Saudi Med J 2004;25(10):1400-1402
96. Aubouy A, Fievet N, Bertin G, et al. Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop Med Int Health 2007;12(7):886-894
97. AlKadi HO. Antimalarial drug toxicity: A review. Chemotherapy 2007;53(6):385-391
98. Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991;45(1):86-91
99. Nosten F, Vincenti M, Simpson J, et al. The effects of mefloquine treatment in pregnancy. Clin Infect Dis 1999;28(4):808-815
100. Steketee RW, Wirima JJ, Slutsker L, et al. Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: Efficacy of chloroquine and mefloquine in rural Malawi. Am J Trop Med Hyg 1996;55(1 Suppl):24-32
101. Ward SA, Sevene EJ, Hastings IM, et al. Antimalarial drugs and pregnancy: Safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 2007;7(2):136-144
102. Phillips-Howard PA, Steffen R, Kerr L, et al. Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J Travel Med 1998;5(3):121-126
103. ter Kuile FO, Nosten F, Thieren M, et al. High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis 1992;166(6):1393-1400
104. ter Kuile FO, Nosten F, Luxemburger C, et al. Mefloquine treatment of acute falciparum malaria: A prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ 1995;73(5):631-642
105. Clerk CA, Bruce J, Affipunguh PK, et al. A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana. J Infect Dis 2008; 198(8):1202-1211
106. Nosten F, McGready R, d'Alessandro U, et al. Antimalarial drugs in pregnancy: A review. Curr Drug Saf 2006;1(1):1-15
107. Rahangdale L, Guerry S, Bauer HM, et al. An observational cohort study of Chlamydia trachomatis treatment in pregnancy. Sex Transm Dis 2006;33(2):106-110
108. Van Vranken M. Prevention and treatment of sexually transmitted diseases: An update. Am Fam Physician 2007;76(12):1827-1832
109. WHO. WHO guidelines for the treatment of malaria. World Health Organization WHM; Geneva: 2010; WHO/HTM/MAL
110. Nosten F, McGready R, Mutabingwa T. Case management of malaria in pregnancy. Lancet Infect Dis 2007;7(2):118-125
111. McGready R, Cho T, Keo NK, et al. Artemisinin antimalarials in pregnancy: A prospective treatment study of 539 episodes of multidrug-resistant plasmodium falciparum. Clin Infect Dis 2001;33(12):2009-2016
112. Sokhna C, Cisse B, Ba el H, et al. A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS One 2008;3(1):e1471
113. Worrall E, Morel C, Yeung S, et al. The economics of malaria in pregnancy-a review of the evidence and research priorities. Lancet Infect Dis 2007;7(2):156-168
114. Goodman CA, Coleman PG, Mills AJ. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet 1999;354(9176):378-385
115. Goodman CA, Coleman PG, Mills AJ. The cost-effectiveness of antenatal malaria prevention in sub-Saharan Africa. Am J Trop Med Hyg 2001; 64(1-2 Suppl):45-56
116. Schultz LJ, Steketee RW, Chitsulo L, Wirima JJ. Antimalarials during pregnancy: A cost-effectiveness analysis. Bull World Health Organ 1995;73(2):207-214
117. Schultz LJ, Steketee RW, Chitsulo L, et al. Evaluation of maternal practices, efficacy, and cost-effectiveness of alternative antimalarial regimens for use in pregnancy: Chloroquine and sulfadoxine-pyrimethamine. Am J Trop Med Hyg 1996;55(1 Suppl):87-94
118. Breman JG, Mills A, Snow RW, et al. Conquering malaria. Chapter 21 in Disease control priorities in developing countries. World Bank and Oxford University Press: WASHINGTON; 2006
119. Mbonye AK, Hansen KS, Bygbjerg IC, Magnussen P. Intermittent preventive treatment of malaria in pregnancy: The incremental cost-effectiveness of a new delivery system in Uganda. Trans R Soc Trop Med Hyg 2008;102(7):685-693
120. Hill J, Kazembe P. Reaching the Abuja target for intermittent preventive treatment of malaria in pregnancy in African women: A review of progress and operational challenges. Trop Med Int Health 2006;11(4):409-418
121. Crawley J, Hill J, Yartey J, et al. From evidence to action? Challenges to policy change and programme delivery for malaria in pregnancy. Lancet Infect Dis 2007;7(2):145-155
122. Sicuri E, Bardaji A, Nhampossa T, et al. Cost-effectiveness of intermittent preventive treatment of malaria in pregnancy in southern Mozambique. PLoS One 2010;5(10):e13407
123. Hutton G, Schellenberg D, Tediosi F, et al. Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania. Bull World Health Organ 2009;87(2):123-129
124. Conteh L, Sicuri E, Manzi F, et al. The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa. PLoS ONE 2010;5(6):e10313
125. Ceesay SJ, Casals-Pascual C, Erskine J, et al. Changes in malaria indices between 1999 and 2007 in the Gambia: A retrospective analysis. Lancet 2008;372(9649):1545-1554
126. O'Meara WP, Bejon P, Mwangi TW, et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 2008;372(9649):1555-1562
127. WHO. World health organization. The World malaria Report; Geneva, Switzerland: 2010
128. Feng G, Simpson JA, Chaluluka E, et al. Decreasing burden of malaria in pregnancy in Malawian women and its relationship to use of intermittent preventive therapy or bed nets. PLoS One 2010;5(8):e12012
129. Garner P, Gulmezoglu AM. Drugs for preventing malaria in pregnant women. Cochrane Database Syst Rev 2006(4):CD000169
130. Greenwood B. Anti-malarial drugs and the prevention of malaria in the population of malaria endemic areas. Malar J 2010;9(Suppl 3):S2
131. Gosling RD, Cairns ME, Chico RM, Chandramohan D. Intermittent preventive treatment against malaria: An update. Expert Rev Anti Infect Ther 2010;8(5):589-606
132. Tagbor H, Bruce J, Agbo M, et al. Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: A randomised controlled non-inferiority trial. PLoS One 2011;5(12):e14425
133. Martinez-Espinosa FE, Daniel-Ribeiro CT, Alecrim WD. Malaria during pregnancy in a reference centre from the Brazilian Amazon: Unexpected increase in the frequency of Plasmodium falciparum infections. Mem Inst Oswaldo Cruz 2004;99(1):19-21
134. Rodriguez-Morales AJ, Sanchez E, Vargas M, et al. Pregnancy outcomes associated with plasmodium vivax malaria in northeastern Venezuela. Am J Trop Med Hyg 2006;74(5):755-757
135. Nosten F, McGready R, Simpson JA, et al. Effects of plasmodium vivax malaria in pregnancy. Lancet 1999;354(9178):546-549
136. Singh N, Shukla MM, Sharma VP. Epidemiology of malaria in pregnancy in central India. Bull World Health Organ 1999;77(7):567-572
137. Singh N, Saxena A, Shrivastava R. Placental Plasmodium vivax infection and congenital malaria in central India. Ann Trop Med Parasitol 2003;97(8):875-878
138. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2004(2):CD000363
139. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against plasmodium falciparum infection and disease in young African children: Randomised controlled trial. Lancet 2004;364(9443):1411-1420
140. Griffin JT, Cairns M, Ghani AC, et al. Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS One 2010;5(9):e12618
141. Alexander N, Sutherland C, Roper C, et al. Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance. Malar J 2007;6:9
142. Cisse B, Sokhna C, Boulanger D, et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: A randomised, placebo-controlled, double-blind trial. Lancet 2006;367(9511):659-667
143. Greenwood B. Review: Intermittent preventive treatment-a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. Trop Med Int Health 2006;11(7):983-991